Prevalence of malaria among febrile patients and assessment of efficacy of artemether-lumefantrine and artesunate-amodiaquine for uncomplicated malaria in Dolisie, Republic of the Congo

Table 4 Treatment response of Congolese children to AL and ASAQ in Dolisie

Outcome	Number of patients (%; 95% CI)
	AL	ASAQ
Number of patients	61	60
PCR‑uncorrected outcome
Withdrawn or lost to follow up	3	3
Per protocol population	58	57
ETF [95% CI]	0 (0) [0–6.2]	1 (1.8) [0–9.4]
LCF [95% CI]	1 (1.7) [0–9.2]	6 (10.5) [4.0–21.5]
LPF [95% CI]	1 (1.7) [0–9.2]	1 (1.8) [0–9.4]
ACPR [95% CI]	56 (96.6) [88.1–99.6]	49 (86.0) [74.2–93.7]
PCR corrected outcome
Withdrawn	0	2
Lost to follow up	3	1
Reinfection (censored)	1	5
Per protocol population	57	52
ETF [95% CI]	0 (0) [0–6.3]	1 (1.9) [0–10.3]
LCF [95% CI]	1 (1.8) [0–9.4]	2 (3.8) [0.5–13.2]
LPF [95% CI]	0 (0) [0–6.3]	0 (0) [0–6.8]
ACPR [95% CI]	56 (98.2) [90.6–100]	49 (94.2) [84.1–98.8]

95% CI 95% confidence interval, ACPR adequate clinical and parasitological response, AL artemether-lumefantrine; ASAQ artesunate-amodiaquine, ETF early therapeutic failure, LCF late clinical failure, LPF late parasitological failure, PCR polymerase chain reaction

ISSN: 1475-2875